TransMedics Group (NASDAQ: TMDX) reported Q3 EPS of ($0.78), $0.62 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $66.4 million versus the consensus estimate of $49.19 million.

GUIDANCE:

TransMedics Group sees FY2023 revenue of $222-230 million, versus prior of $180-$190 million and the consensus of $194.18 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.